ZeTox – Toxicology Services

BY
OUR
PLATFORMS

icon-zeglobaltox ZeGlobalTox – 3 Analysis Into a 1 Procedure

ZeGlobalTox is a novel experimental procedure that integrates the analysis of cardio-, neuro-, and hepatotoxicity into a single procedure validated through the evaluation of known toxic compounds. Interestingly, the three sequential assays are performed in the same larvae, allowing the reduction of animals and streamlining the experimental pipeline. The high predictivity of ZeGlobalTox allows reducing the use of rodents and other mammals in organ-toxicity screening.

Advantages

Simultaneous assessment of Neurotoxicity, Cardiotoxicity, and Hepatotoxicity.

Short lead times for results.

Compliance with the 3R´s (Refine, Replace, and Reduce).

Method description

Phase I: The Fast Acute Toxicity test is performed to determine the benchmark dose (BMD) in which mortality and gross teratogenic defects are absent.

Phase II: A transgenic line expressing GFP in cardiomyocytes and RFP in hepatocytes are treated from 96 to 128 hpf with the benchmark dose (BMD) determined in Phase I. During this incubation period, cardio-, neuro-, and hepatotoxicity are determined sequentially in the same larvae. 

Figure. ZeGlobalTox experimental phases I (A) and II (B)

Readouts

References

  1. 2017 Cornet et al - ZeGlobalTox - An Innovative Approach to Address Organ Drug Toxicity Using Zebrafish.